Faeth Therapeutics annual return on equity
2021
2022
2023
2024
2025
Faeth Therapeutics Return on Equity (ROE) Growth & History (FTH)
Faeth Therapeutics's return on equity was −74.01% for fiscal 2025.
View full Faeth Therapeutics company overviewFaeth Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −74.01% | −15.61 pp |
| 2024 | 2024-12-31 | −58.40% | −17.87 pp |
| 2023 | 2023-12-31 | −40.52% | −1.64 pp |
| 2022 | 2022-12-31 | −38.88% | +42.82 pp |
| 2021 | 2021-12-31 | −81.70% | — |
Faeth Therapeutics quarterly return on equity
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −89.75% | −73.10 pp |
| Q4 2025 | 2025-12-31 | −22.67% | −4.21 pp |
| Q3 2025 | 2025-09-30 | −18.16% | −3.35 pp |
| Q2 2025 | 2025-06-30 | −16.65% | −3.74 pp |
| Q1 2025 | 2025-03-31 | −19.51% | −6.55 pp |
| Q4 2024 | 2024-12-31 | −18.46% | −7.55 pp |
| Q3 2024 | 2024-09-30 | −14.81% | −5.32 pp |
| Q2 2024 | 2024-06-30 | −12.91% | −2.12 pp |
| Q1 2024 | 2024-03-31 | −12.96% | −2.69 pp |
| Q4 2023 | 2023-12-31 | −10.91% | +0.34 pp |
| Q3 2023 | 2023-09-30 | −9.49% | +1.70 pp |
| Q2 2023 | 2023-06-30 | −10.79% | −2.72 pp |
| Q1 2023 | 2023-03-31 | −10.27% | −1.46 pp |
| Q4 2022 | 2022-12-31 | −11.25% | −5.04 pp |
| Q3 2022 | 2022-09-30 | −11.18% | −5.10 pp |
| Q2 2022 | 2022-06-30 | −8.07% | −2.22 pp |
| Q1 2022 | 2022-03-31 | −8.80% | +5.08 pp |
| Q4 2021 | 2021-12-31 | −6.21% | — |
| Q3 2021 | 2021-09-30 | −6.08% | — |
| Q2 2021 | 2021-06-30 | −5.84% | — |
| Q1 2021 | 2021-03-31 | −13.89% | — |
Faeth Therapeutics return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Faeth Therapeutics's return on equity increased from −81.70% to −74.01%, a change of +7.69 percentage points. The latest reported quarter, Q2 2026, shows −89.75%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Faeth Therapeutics source filings ↗